Stryker's Surpass buy feeds growing neurovasc unit; pares down 2012 and 2013 earnings guidance
This article was originally published in Clinica
Stryker has bolstered its neurovascular offering by agreeing to acquire Israeli firm Surpass Medical in a deal worth up to $135 million. Privately-held Surpass has developed a device called NeuroEndoGraft, a self-expanding cobalt chromium mesh designed to treat brain aneurysms by redirecting blood flow away from the affected area, allowing a stable clot to be formed in the aneurysm pouch. The device is implanted via a minimally-invasive catheter-based procedure.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.